Despite differences in performance compared to MRS, we propose that DSC perfusion holds promise for predicting IDH and 1p19q status in gliomas, and that the value of these modalities lies not in their differences but in their complementary nature. The gene discussed is IDH1; the disease is central nervous system cancer.